Cargando…
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, result in dose delays and reductions and, ultimately, reduce cancer survival. Over the past decade, the availability of biosimilar filgrastim (short-acting granulocyte colony-stim...
Autores principales: | Cornes, Paul, Gascon, Pere, Vulto, Arnold G., Aapro, Matti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211191/ https://www.ncbi.nlm.nih.gov/pubmed/32232676 http://dx.doi.org/10.1007/s40259-020-00411-4 |
Ejemplares similares
-
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018) -
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
por: Ebbers, Hans C., et al.
Publicado: (2016) -
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019) -
Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015) -
An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)